SQZ Biotechnologies Company
US ˙ OTCPK ˙ US78472W1045

Introduction

This page provides a comprehensive analysis of the known insider trading history of Polaris Management Co. VII, L.L.C.. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

See Highest Ranking Insiders
Companies with Reported Insider Positions

The SEC filings indicate Polaris Management Co. VII, L.L.C. has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
10% Owner 909,090
US:SQZ / SQZ Biotechnologies Co 10% Owner 0
US:MTCR / Metacrine Inc 10% Owner 0
US:SYRS / Syros Pharmaceuticals, Inc. 10% Owner 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Polaris Management Co. VII, L.L.C.. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases SQZB / SQZ Biotechnologies Company - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in SQZB / SQZ Biotechnologies Company. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2020-11-03 SQZ Polaris Management Co. VII, L.L.C. 16,346 16.0000 16,346 16.0000 261,536 55 34.58 303,709 116.12
2020-11-03 SQZ Polaris Management Co. VII, L.L.C. 233,654 16.0000 233,654 16.0000 3,738,464

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SQZB / SQZ Biotechnologies Company Insider Trades
Insider Sales SQZB / SQZ Biotechnologies Company - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in SQZB / SQZ Biotechnologies Company. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SQZB / SQZ Biotechnologies Company Insider Trades
Insider Purchases SYRS / Syros Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in SQZB / SQZ Biotechnologies Company. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2016-07-06 SYRS Polaris Management Co. VII, L.L.C. 373,847 12.5000 37,385 125.0000 4,673,088 348 185.7 2,269,122 48.56
2016-07-06 SYRS Polaris Management Co. VII, L.L.C. 26,153 12.5000 2,615 125.0000 326,912

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SYRS / Syros Pharmaceuticals, Inc. Insider Trades
Insider Sales SYRS / Syros Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in SQZB / SQZ Biotechnologies Company. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SYRS / Syros Pharmaceuticals, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Polaris Management Co. VII, L.L.C. as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change		 Share
Price		 Tran
Value		 Remaining
Value
2024-10-22 2024-10-15 4/A CAMP Camp4 Therapeutics Corp
Common Stock 		P - Purchase 909,090 909,090 11.00 9,999,990 9,999,990
2024-10-22 2024-10-15 4/A CAMP Camp4 Therapeutics Corp
Common Stock 		C - Conversion 24,745 112,193 28.30
2024-10-22 2024-10-15 4/A CAMP Camp4 Therapeutics Corp
Common Stock 		C - Conversion 353,718 1,603,779 28.30
2024-10-22 2024-10-15 4/A CAMP Camp4 Therapeutics Corp
Common Stock 		C - Conversion 87,448 87,448
2024-10-22 2024-10-15 4/A CAMP Camp4 Therapeutics Corp
Common Stock 		C - Conversion 1,250,061 1,250,061
2024-10-15 2024-10-15 4 CAMP Camp4 Therapeutics Corp
Common Stock 		P - Purchase 909,090 909,090 11.00 9,999,990 9,999,990
2024-10-15 2024-10-15 4 CAMP Camp4 Therapeutics Corp
Common Stock 		C - Conversion 24,745 112,193 28.30
2024-10-15 2024-10-15 4 CAMP Camp4 Therapeutics Corp
Common Stock 		C - Conversion 353,718 1,603,779 28.30
2024-10-15 2024-10-15 4 CAMP Camp4 Therapeutics Corp
Common Stock 		C - Conversion 87,448 87,448
2024-10-15 2024-10-15 4 CAMP Camp4 Therapeutics Corp
Common Stock 		C - Conversion 1,250,061 1,250,061
2020-11-03 2020-11-03 4 SQZ SQZ Biotechnologies Co
Series D Convertible Preferred Stock 		C - Conversion -348,725 0 -100.00
2020-11-03 2020-11-03 4 SQZ SQZ Biotechnologies Co
Series D Convertible Preferred Stock 		C - Conversion -24,397 0 -100.00
2020-11-03 2020-11-03 4 SQZ SQZ Biotechnologies Co
Series C Convertible Preferred Stock 		C - Conversion -630,672 0 -100.00
2020-11-03 2020-11-03 4 SQZ SQZ Biotechnologies Co
Series C Convertible Preferred Stock 		C - Conversion -44,120 0 -100.00
2020-11-03 2020-11-03 4 SQZ SQZ Biotechnologies Co
Series B Convertible Preferred Stock 		C - Conversion -807,096 0 -100.00
2020-11-03 2020-11-03 4 SQZ SQZ Biotechnologies Co
Series B Convertible Preferred Stock 		C - Conversion -56,462 0 -100.00
2020-11-03 2020-11-03 4 SQZ SQZ Biotechnologies Co
Series A Convertible Preferred Stock 		C - Conversion -412,608 0 -100.00
2020-11-03 2020-11-03 4 SQZ SQZ Biotechnologies Co
Series A Convertible Preferred Stock 		C - Conversion -28,863 0 -100.00
2020-11-03 2020-11-03 4 SQZ SQZ Biotechnologies Co
Common Stock 		P - Purchase 233,654 2,549,306 10.09 16.00 3,738,464 40,788,896
2020-11-03 2020-11-03 4 SQZ SQZ Biotechnologies Co
Common Stock 		P - Purchase 16,346 178,340 10.09 16.00 261,536 2,853,440
2020-11-03 2020-11-03 4 SQZ SQZ Biotechnologies Co
Common Stock 		C - Conversion 2,315,652 2,315,652
2020-11-03 2020-11-03 4 SQZ SQZ Biotechnologies Co
Common Stock 		C - Conversion 161,994 161,994
2020-09-22 2020-09-18 4 MTCR Metacrine, Inc.
Series C Convertible Preferred Stock 		C - Conversion -15,118 0 -100.00
2020-09-22 2020-09-18 4 MTCR Metacrine, Inc.
Series C Convertible Preferred Stock 		C - Conversion -216,106 0 -100.00
2020-09-22 2020-09-18 4 MTCR Metacrine, Inc.
Series B Convertible Preferred Stock 		C - Conversion -20,585 0 -100.00
2020-09-22 2020-09-18 4 MTCR Metacrine, Inc.
Series B Convertible Preferred Stock 		C - Conversion -451,666 0 -100.00
2020-09-22 2020-09-18 4 MTCR Metacrine, Inc.
Series A Convertible Preferred Stock 		C - Conversion -128,201 0 -100.00
2020-09-22 2020-09-18 4 MTCR Metacrine, Inc.
Series A Convertible Preferred Stock 		C - Conversion -1,832,582 0 -100.00
2020-09-22 2020-09-18 4 MTCR Metacrine, Inc.
Common Stock 		C - Conversion 15,118 178,942 9.23
2020-09-22 2020-09-18 4 MTCR Metacrine, Inc.
Common Stock 		C - Conversion 216,106 2,715,316 8.65
2020-09-22 2020-09-18 4 MTCR Metacrine, Inc.
Common Stock 		C - Conversion 20,585 163,824 14.37
2020-09-22 2020-09-18 4 MTCR Metacrine, Inc.
Common Stock 		C - Conversion 451,666 2,499,210 22.06
2020-09-22 2020-09-18 4 MTCR Metacrine, Inc.
Common Stock 		C - Conversion 128,201 143,239 852.51
2020-09-22 2020-09-18 4 MTCR Metacrine, Inc.
Common Stock 		C - Conversion 1,832,582 2,047,544 852.51
2020-09-22 2020-09-18 4 MTCR Metacrine, Inc.
Common Stock 		P - Purchase 15,038 15,038 13.00 195,494 195,494
2020-09-22 2020-09-18 4 MTCR Metacrine, Inc.
Common Stock 		P - Purchase 214,962 214,962 13.00 2,794,506 2,794,506
2016-07-07 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Series B Preferred Stock 		C - Conversion -83,129 0 -100.00
2016-07-07 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Series B Preferred Stock 		C - Conversion -4,366,825 0 -100.00
2016-07-07 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock 		P - Purchase 26,153 48,320 117.98 12.50 326,912 604,000
2016-07-07 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock 		P - Purchase 373,847 1,538,333 32.10 12.50 4,673,088 19,229,162
2016-07-07 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock 		C - Conversion 22,167 22,167
2016-07-07 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock 		C - Conversion 1,164,486 1,164,486
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)